REYOBIQ™ (rhenium Re186 obisbemeda)
Recurrent Glioblastoma
Key Facts
About Plus Therapeutics
Plus Therapeutics is focused on developing targeted radiotherapeutics for rare and difficult-to-treat cancers, with a mission to deliver high-dose radiation precisely to tumors. The company's core innovation is a proprietary platform combining Rhenium isotopes, nanoliposomes, and biodegradable microspheres to enable localized, image-guided therapy. Key achievements include promising Phase 1 data for its lead candidate, REYOBIQ™, in recurrent glioblastoma and leptomeningeal metastases, and the advancement of a next-generation liver cancer program. Its strategy centers on advancing its clinical pipeline in high-unmet-need oncology indications while leveraging theranostic capabilities.
View full company profileAbout Plus Therapeutics
Plus Therapeutics is focused on developing targeted radiotherapeutics for rare and difficult-to-treat cancers, with a mission to deliver high-dose radiation precisely to tumors. The company's core innovation is a proprietary platform combining Rhenium isotopes, nanoliposomes, and biodegradable microspheres to enable localized, image-guided therapy. Key achievements include promising Phase 1 data for its lead candidate, REYOBIQ™, in recurrent glioblastoma and leptomeningeal metastases, and the advancement of a next-generation liver cancer program. Its strategy centers on advancing its clinical pipeline in high-unmet-need oncology indications while leveraging theranostic capabilities.
View full company profileAbout Plus Therapeutics
Plus Therapeutics is focused on developing targeted radiotherapeutics for rare and difficult-to-treat cancers, with a mission to deliver high-dose radiation precisely to tumors. The company's core innovation is a proprietary platform combining Rhenium isotopes, nanoliposomes, and biodegradable microspheres to enable localized, image-guided therapy. Key achievements include promising Phase 1 data for its lead candidate, REYOBIQ™, in recurrent glioblastoma and leptomeningeal metastases, and the advancement of a next-generation liver cancer program. Its strategy centers on advancing its clinical pipeline in high-unmet-need oncology indications while leveraging theranostic capabilities.
View full company profileTherapeutic Areas
Other Recurrent Glioblastoma Drugs
| Drug | Company | Phase |
|---|---|---|
| SonoCloud® / SONOBIRD Trial | CarThera | Pivotal/Phase 3 |